Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib PK in renal impairment
NCT02431481Phase 1Completed
- Sponsor
- Novartis
- Start
- Oct 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of ribociclib in breast cancer (5 arms), sponsored by Novartis. Primary endpoint: Primary Pharmacokinetics parameters of LEE011 at 14 days. Started Oct 2015; status: completed.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02431481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02431481.